Amgen's oncology portfolio continues to evolve, with AMG 193, a PRMT5 inhibitor for MTAP-null tumors, showing early promise. Phase I data revealed objective response rates of 18% for NSCLC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback